XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it. Here is a review of what 2020 served up.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Pharmaceutical Technology

MAY 22, 2023

It comes with quick vaccine fill-finish capabilities and offers end-to-end pharmaceutical development and manufacturing services. With this expansion we are strategically prepared, more than ever, to respond to our customers’ needs by supporting the accelerated delivery of critical vaccines and medicines to patients.”

Genetic Analysis 147

Genetic Analysis Manufacturing Drugs Vaccination 147

XTalks

JULY 19, 2022

The US Food and Drug Administration (FDA) has given emergency use authorization (EUA) to Novavax’s COVID-19 vaccine, making it the fourth authorized vaccine in the US against COVID-19. The vaccine is branded as Nuvaxovid outside the US with approvals/authorizations in Canada, the EU, UK, Australia and South Korea.

Vaccination 94

Vaccination Vaccine Protein Clinical Trials 94

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

DECEMBER 16, 2022

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.

Vaccination 96

Vaccination Vaccine Production Licensing 96

XTalks

NOVEMBER 11, 2021

The US National Institutes of Health (NIH) and Moderna continue to be at loggerheads in a COVID-19 vaccine patent spat, with the federal health agency not ruling out legal action against the Cambridge, Massachusetts-based biotech. Related: Moderna Unwilling to Share COVID-19 Vaccine Formula Amid Vaccine Inequities.

Vaccination 98

Vaccination Vaccine Scientist Contract Manufacturing 98

XTalks

DECEMBER 20, 2021

The World Health Organization (WHO) has backed Novavax’s COVID-19 vaccine, Covovax (NVX-CoV2373), by granting it an emergency use listing (EUL). The company is awaiting on authorization of its vaccine from regulatory health bodies around the world, including the US Food and Drug Administration (FDA) and Health Canada.

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

XTalks

SEPTEMBER 15, 2021

With RNA being the popular new “it” molecule in genetic research, Ayesha discusses Eli Lilly’s new partnership with biotech company ProQR to develop RNA-based therapeutics in this episode. The team discusses how the success of the mRNA COVID-19 vaccines have heightened interest in RNA-based therapies. New Study Shows Less May Be More.

RNA 52

RNA Life Science Development Genetics 52

XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. A small study from John Hopkins University has shown that a third dose of a COVID-19 vaccine could indeed help immunocompromised patients.

Vaccination 104

Vaccination Vaccine Antibody Immune Response 104

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

NOVEMBER 23, 2020

Adding to recent announcements from Pfizer and Moderna on the efficacy of their COVID-19 vaccine candidates, AstraZeneca and Oxford revealed today that their vaccine contender is 70 percent effective, and could be as high as 90 percent. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

JUNE 16, 2021

Novavax shared the latest data from its ongoing late-stage COVID-19 vaccine trial, which shows that its yet-to-be authorized shot provides 100 percent protection against moderate and severe disease and has an overall efficacy of 90.4 Related: Latest Data from Novavax COVID-19 Vaccine Trial Involving B.1.351

Vaccination 98

Vaccination Vaccine Protein Trials 98

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 That analysis also showed that the Novavax COVID-19 vaccine was 96.4

Protein 97

Protein Vaccination Vaccine Trials 97

XTalks

SEPTEMBER 30, 2020

The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Casanova’s lab is now searching for the genetic driver behind the autoantibodies. Autoimmune Attack and COVID-19 Symptom Severity.

Antibody 135

Antibody Genetics Research In-Vitro 135

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

JUNE 15, 2022

Last week, Novavax announced that it received positive feedback from the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the safety and efficacy of its COVID-9 vaccine (NVX-CoV2373). The Novavax COVID-19 Vaccine Candidate. The vaccine is given in two doses.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

SEPTEMBER 8, 2020

The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus. AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO of AMRI, in a statement.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

JUNE 20, 2022

Alnylam has also been in the news recently over claims that it holds the patent for the lipid nanoparticle technology Pfizer and Moderna used in their COVID-19 vaccines. Alnylam filed lawsuits against both companies in March this year over the alleged patent infringements.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

NOVEMBER 10, 2020

Update (November 11, 2020): Quebec-based biopharmaceutical company Medicago has announced positive results from a Phase I trial of its candidate plant-derived vaccine. Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

MAY 11, 2023

Fundraising and investment are a core pillar of not just BioTrinity events but of the drug discovery industry at large, so events such as Tuesday’s keynote, Investment Trends for the Life Sciences Industry, are critical for members of the industry.

Life Science 52

Life Science Genetics Vaccination Vaccine 52

The Pharma Data

JULY 29, 2021

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines. HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. President of the Global Vaccine Business Unit, Takeda. 2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. The widespread recognition of the term “mRNA” by people around the world can be attributed to the development of Covid-19 vaccines.” We believe it can now do the same for rare diseases.” “We

RNA 52

RNA Protein Vaccination Vaccine 52

Drug Discovery World

APRIL 27, 2023

The report notes that the focus on science and pharma throughout the Covid-19 pandemic has resulted in the emergence of new locations as life science hubs and name checks Boston, Massachusetts and San Francisco, California as examples of centres with heightened investment appeal in the life sciences 1.

Life Science 52

Life Science Drugs Research Gene Splicing 52

pharmaphorum

JULY 7, 2022

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. Read on to find out about reaching the gold standard of lung cancer screening, the promise of therapeutic cancer vaccines, why diversity is essential in oncology trials, and much more. Realising the promise of cancer vaccines.

Vaccination 52

Vaccination Vaccine Life Science Trials 52

Pharmaceutical Technology

MAY 15, 2023

A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. OVs can be attenuated natural viruses or recombinant viruses.

Protein 130

Protein Gene Genetics Gene Therapy 130

XTalks

JANUARY 11, 2023

Importantly, preliminary data shows that bivalent COVID-19 vaccines that target the parent strain of Omicron should provide protection against XBB.1.5 Experts also say the reason we’re seeing the continuing emergence of new variants is global vaccine inequity. likely emerged through the genetic recombination of the Omicron BA.2.10.1

Scientist 98

Scientist Vaccination Vaccine Genetics 98

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The company's lead asset involving this technology is isaralgagene civaparvovec (ST 920).

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

XTalks

JANUARY 4, 2024

Hemophilia B, also known as congenital Factor IX (FIX) deficiency or Christmas disease, is a rare genetic bleeding disorder caused by a deficiency or defect in the FIX clotting protein. Pfizer said that according to the World Federation of Hemophilia, more than 38,000 people worldwide were living with hemophilia B in 2021.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

XTalks

JANUARY 14, 2021

Related: COVID-19 Vaccine and Drug Development Coverage. Hahn, MD said, “The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients.”. The arise of new variants contributes to genetic diversity in the pool of circulating viral strains.

Genetics 98

Genetics Genome Genomics Protein 98

Drug Discovery World

NOVEMBER 27, 2023

By Anis H Khimani , PhD, Senior Strategy Leader, Life Sciences strategy group, Revvity, Inc. link] About the author Anis is within the strategy group in Life Sciences at Revvity, Inc. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News , Mary Ann Liebert, Inc.

Production 59

Production Engineer Gene Editing Gene 59

XTalks

APRIL 1, 2022

This is a problem as responses to treatments can vary between different racial groups owing to differences in genetics, physiology and lifestyle factors. They spoke about an NHLBI initiative that was created to help foster the inclusion of minority groups in clinical trials for COVID-19 vaccines and therapies. Read on to learn more.

Clinical Trials 126

Clinical Trials Clinical Trials Trials Vaccination 126

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. Rajini Jayasuriya is a senior associate in the Life Sciences Practice at CRA, based in the Washington, DC office.

Life Science 128

Life Science Genetics Development Vaccination 128

Drug Discovery World

FEBRUARY 28, 2024

In glioblastoma, as with many other highly recurrent cancers, tumour cells that escape treatment develop multiple genetic adaptations that allow them to proliferate. The Gladstone team realised that these mutated cells have a unique genetic signature that could be targeted. “We

Development 64

Development Research Drugs Antibody 64